Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

517 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
ABO-mismatched marrow processing for transplantation: results of 114 procedures and analysis of immediate adverse events and hematopoietic recovery.
Larghero J, Rea D, Esperou H, Biscay N, Maurer MN, Lacassagne MN, Ternaux B, Traineau R, Yakouben K, Dosquet C, Socié G, Gluckman E, Benbunan M, Marolleau JP. Larghero J, et al. Among authors: rea d. Transfusion. 2006 Mar;46(3):398-402. doi: 10.1111/j.1537-2995.2006.00735.x. Transfusion. 2006. PMID: 16533282
A specific time course for mobilization of peripheral blood CD34+ cells after plerixafor injection in very poor mobilizer patients: impact on the timing of the apheresis procedure.
Lefrère F, Mauge L, Réa D, Ribeil JA, Dal Cortivo L, Brignier AC, Aoun C, Larghéro J, Cavazzana-Calvo M, Micléa JM. Lefrère F, et al. Among authors: rea d. Transfusion. 2013 Mar;53(3):564-9. doi: 10.1111/j.1537-2995.2012.03744.x. Epub 2012 Jun 21. Transfusion. 2013. PMID: 22725259 Clinical Trial.
Nilotinib and peginterferon alfa-2a for newly diagnosed chronic-phase chronic myeloid leukaemia (NiloPeg): a multicentre, non-randomised, open-label phase 2 study.
Nicolini FE, Etienne G, Dubruille V, Roy L, Huguet F, Legros L, Giraudier S, Coiteux V, Guerci-Bresler A, Lenain P, Cony-Makhoul P, Gardembas M, Hermet E, Rousselot P, Amé S, Gagnieu MC, Pivot C, Hayette S, Maguer-Satta V, Etienne M, Dulucq S, Rea D, Mahon FX. Nicolini FE, et al. Among authors: rea d. Lancet Haematol. 2015 Jan;2(1):e37-46. doi: 10.1016/S2352-3026(14)00027-1. Epub 2015 Jan 7. Lancet Haematol. 2015. PMID: 26687426 Clinical Trial.
Longer treatment duration and history of osteoarticular symptoms predispose to tyrosine kinase inhibitor withdrawal syndrome.
Berger MG, Pereira B, Rousselot P, Cony-Makhoul P, Gardembas M, Legros L, Escoffre-Barbe M, Nicolini FE, Saugues S, Lambert C, Réa D, Guerci-Bresler A, Giraudier S, Guilhot J, Saussele S, Mahon FX; (France Intergroupe des Leucémies Myéloïdes Chroniques). Berger MG, et al. Among authors: rea d. Br J Haematol. 2019 Nov;187(3):337-346. doi: 10.1111/bjh.16083. Epub 2019 Jul 4. Br J Haematol. 2019. PMID: 31271217 Free article.
Thrombocytapheresis and sequential chemotherapy for extreme symptomatic thrombocytosis secondary to myelofibrosis: a case report.
Debureaux PE, Brignier A, Soret-Dulphy J, Réa D, Michonneau D, Peffault de Latour R, Sicre de Fontbrune F, Pagliuca S, Parquet N, Prata HP, Marouf A, Xhaard A, Kiladjian JJ, Socié G, Robin M. Debureaux PE, et al. Among authors: rea d. Ann Hematol. 2020 Apr;99(4):897-898. doi: 10.1007/s00277-020-03948-0. Epub 2020 Feb 7. Ann Hematol. 2020. PMID: 32030449 No abstract available.
517 results